Ovarian Cancer Vaccine Candidate Bio-production to Begin
Vancouver-based BioVaxys Technology Corp. announced today that it had signed the definitive exclusive bioproduction agreement with BioElpida S.A.S. of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys' vaccine candidate for Stage III/Stage IV ovarian cancer.
BioVaxys expects to prepare its regulatory submission for a Phase I study of BVX-0918A in Stage III/Stage IV ovarian cancer near the end of 2021, with vaccine supply for the planned clinical study available in May 2022.
Kenneth Kovan, Co-Founder, President, and Chief Operating Officer of BioVaxys, commented in a press release, "BioElpida's technical experience and previous work on early generations of our cancer vaccine platform will be a significant advantage in our efforts to provide hope to those who have advanced ovarian cancer."
BioVaxys is also collaborating on the ovarian cancer vaccine clinical program with Spanish biopharma company ProCare Health Iberia S.A.S., which plans to submit a clinical trial application BVX-0918A to the European Medicines Agency later this year for a compassionate use approval in Stage III & Stage IV ovarian cancer.
Worldwide, over 300,000 women are diagnosed with ovarian cancer each year, the leading cause of death from gynecologic malignancy in the USA.
BioVaxys Technology Corp. is a British Columbia-registered, an early-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.